Share Name Share Symbol Market Type Share ISIN Share Description
Allied Minds LSE:ALM London Ordinary Share GB00BLRLH124 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +3.40p +2.10% 165.00p 166.50p 167.00p 167.40p 158.40p 167.00p 278,764.00 16:35:12
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 3.3 -98.0 -36.0 - 386.46

Allied Minds Share Discussion Threads

Showing 5651 to 5674 of 5675 messages
Chat Pages: 227  226  225  224  223  222  221  220  219  218  217  216  Older
DateSubjectAuthorDiscuss
24/4/2017
09:37
I generally agree with Woodrot on this as "short time noise" Especially as the penny is yet to drop on (STI) Spin Tork Idiocy & (FW) Fukinhated Wireloose - the other two worthless companies for the bag holders.
liquidkid
22/4/2017
11:27
This one has to start to prove itself now.
r ball
21/4/2017
09:57
Jefferies HOLD tp 195p reiterates
philanderer
21/4/2017
09:47
Neil Woodford has lost his mojo.
skinwalker
20/4/2017
17:06
And another million
philanderer
18/4/2017
21:10
Invesco dumping another couple of million. Still holding plenty.
philanderer
17/4/2017
09:52
Does it make money
mj19
07/4/2017
19:49
This co. is bust, until one of the cos. monetises itself it will continue to haemorrhage cash, it's fooled! Sell once and stay out!
bookbroker
07/4/2017
19:45
What chances that Invesco will continue to liqidate? High (imo) Remember the first loss is often the samllest loss - Memo to Self - Remember this and do not hope for recovery - It is often like the pot of gold at the end of the rainbow - mythical !!
pugugly
07/4/2017
19:17
Invesco dumping a couple of mill , still holding almost 25%
philanderer
06/4/2017
21:35
Jefferies 'hold' and 195p target (from Alphaville this morning)
philanderer
06/4/2017
20:03
His record counts for a hell of a lot, however his reputation was made on value/GARP investments, in profitable and highly cash generative companies. GSK reaffirmed a view again today that pharma is on the cusp of a new era of drug discovery and treatment options. This may be what Woodford sees, however benefiting is a different matter and established global pharma looks the lower risk strategy to me, just IMV.
essentialinvestor
06/4/2017
19:52
Does woodford's opinion count more than anyone else's. Judging by the performance of so many of his holdings in wpct I think not. I bet he thought ALM was good value when it was over 500p, cir. good value when it was over 300p, ver good value when it wsa over 50 p, dddd good value when it was Over £10, not mentioning the infamous Northwest Biotherapeutics. Otherwise one cannot expalin why he has got them all in his top ten holding at one stage if he was not convinced but we all know what has turned out of his conviction, all of them more than halved in value over a two year space.
riskvsreward
06/4/2017
19:26
Vidacos above 8%
philanderer
06/4/2017
10:35
On what basis?.
essentialinvestor
06/4/2017
10:32
Bought in at 1.69 - completely oversold now
asturius101
06/4/2017
10:18
Worth 100p imo.
blueball
06/4/2017
08:39
Well the market cap will now see them fall out of the FTSE 250 at the next reshuffle so maybe that is what is causing the continued weakness as trackers start to bail out.
salpara111
06/4/2017
00:04
"Neil Woodford bats off Allied Minds share plunge as "short-term noise" " Well-known City investor Neil Woodford has dismissed a share price plunge at Allied Minds, which his company owns just under a third of, as "short term noise" which misses the bigger picture. Intellectual property group Allied Minds said on Wednesday that seven of its subsidiaries would be sold or wound down as part of a $146.6m (£118m) writedown of costs, causing its share price to tumble more than 20pc. Mr Woodford, whose company invested an extra £15m in Allied Minds last December, batted off the double-digit fall by arguing that "share price movement can miss the longer-term opportunity". Defending the decision, he said that the "sensible" restructure could help "accelerate the creation of long-term value for shareholders". The subsidiaries which the Boston-based company plans to drop include a tinnitus treatment firm, a food disease killing company and a business which disinfects cashew kernels. Jill Smith, who became Allied's interim chief executive last month after co-founder Chris Silva stepped away from the business, said that this was a "necessary step in refocusing the company on the areas where we have most potential" and would ultimately benefit shareholders. News of the restructure and the subsequent share price reaction, not helped by Silva's sudden departure some weeks earlier, come weeks ahead of Allied's full-year results. Mr Woodford's company is one of the largest shareholders in Allied with a holding of over 28pc, or almost 66 million shares. He is refusing to show any sign of concern, however, insisting that the recent events had not put him off the sector. "The businesses we have backed [in this industry] have diverse portfolios of young, disruptive businesses with significant long-term potential," he said. "Short-term noise and share price movement can miss the longer-term opportunity. The announcement from Allied Minds this morning should be seen in that context." HTTP://www.telegraph.co.uk/business/2017/04/05/neil-woodford-bats-allied-minds-share-plunge-short-term-noise/
philanderer
05/4/2017
22:44
Just an observation having watched numerous GSK presentations and pipeline discussions, have no great industry insight.
essentialinvestor
05/4/2017
21:36
philanderer: Nice find - Anyone reckon Arix Bioscience (ARIX) might go the same way - As essentiallinvestor advises us above most compounds, and from my experience many other medical products, never make it to commercial reality.
pugugly
05/4/2017
21:14
'Allied Minds deals more pain to Woodford and Barnett' HTTP://citywire.co.uk/money/allied-minds-deals-more-pain-to-woodford-and-barnett/a1006419?re=45836&ea=290170&utm_source=BulkEmail_Money_Daily_Summary&utm_medium=BulkEmail_Money_Daily_Summary&utm_campaign=BulkEmail_Money_Daily_Summary
philanderer
05/4/2017
20:02
Look at how many biotechs just GSK work with, it's a huge number. Gives some insight in to the number of compounds that never make it past earliest phase trials, or are discontinued even before then.
essentialinvestor
05/4/2017
19:54
The Oxford Whale: It is not only biotech where WPCT seems to be coming adrift - Looking at the quoted companies RM2 is continuing to fall - Pallets are not out of the wood - to be a cynic. In reality management there initially failed to get the poduction right - slippery - Could it be that WPCT have bought the product promise (as we all tend to do at times) and not done enough reseach on the abilities of the mangements of some of investee companies to deliver? totallly agree with you - virtually impossible to evaluate the progress of many unquoted and not in revenue companies.
pugugly
Chat Pages: 227  226  225  224  223  222  221  220  219  218  217  216  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V: D:20170425 16:40:32